HEALTH TECHNOLOGY

Texas Children's Hospital And Baylor College of Medicine COVID-19 Vaccine Technology Secures Emergency Use Authorization In India

Texas Children Hospital | December 29, 2021

Texas Children's Hospital and Baylor College of Medicine announced today that CORBEVAX™, a protein sub-unit COVID-19 Vaccine, whose technology was created and engineered at its Center for Vaccine Development (CVD), has received Emergency Use Authorization (EUA) approval from the Drugs Controller General of India (DCGI) to launch in India with other underserved countries to follow.

Dubbed "The World's COVID-19 Vaccine", it uses a traditional recombinant protein-based technology that will enable its production at large scales making it widely accessible to inoculate the global population. The initial construct and production process of the vaccine antigen was developed at Texas Children's Hospital CVD, led by co-directors Drs. Maria Elena Bottazzi and Peter Hotez and in-licensed from BCM Ventures, Baylor College of Medicine's integrated commercialization team, to Hyderabad-based vaccine and pharmaceutical company Biological E. Limited (BE).

CORBEVAX™ after completing two Phase III clinical trials involving more than 3000 subjects was found to be safe, well tolerated and immunogenic:

  • CORBEVAX™ demonstrated superior immune response in comparison with COVISHIELD™ vaccine when assessed for Neutralizing Antibody (nAb) Geometric Mean Titers (GMT) against the Ancestral-Wuhan strain and the globally dominant Delta variant. CORBEVAX™ vaccination also generated significant Th1 skewed cellular immune response.
  • CORBEVAX™ nAb GMT against Ancestral-Wuhan strain is indicative of vaccine effectiveness of >90% for prevention of symptomatic infections based on the Correlates of Protection assessment performed during Moderna and Astra-Zeneca vaccine Phase III studies.
  • CORBEVAX™ nAb GMT against the Delta strain indicates a vaccine effectiveness of >80 percent for the prevention of symptomatic infections based on published studies.

While none of the subjects who took CORBEVAX™ or COVISHIELD™ had serious adverse events, CORBEVAX™ had 50 percent fewer adverse events than COVISHIELD™.

In the continuous monitoring of phase II studies, CORBEVAX™ showed high persistence of immune response as indicated by <30% drop in nAb GMT till 6 months second dose as compared to >80% drop observed with majority of the vaccines.

"Protein-based vaccines have been widely used to prevent many other diseases, have proven safety records, and use economies of scale to achieve low-cost scalability across the world," said Dr. Maria Elena Bottazzi, Professor and Associate Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children's Hospital Center for Vaccine Development. "Our decade-long studies advancing coronavirus vaccine prototypes has led to the creation of this vaccine, which will fill the access gap created by the more expensive, newer vaccine technologies and that today are still not able to be quickly scaled for global production."

The need for safe, streamlined, low-cost vaccines for middle- to low-income countries is central to the world's fight against the COVID-19 pandemic. Without widespread vaccination of populations in the Global South, additional virus variants will arise, hindering the progress achieved by currently available vaccines in the United States and other Western countries.

"This announcement is an important first step in vaccinating the world and halting the pandemic. Our vaccine technology offers a path to address an unfolding humanitarian crisis, namely the vulnerability the low- and middle-income countries face against the delta variant," said Dr. Peter Hotez, Professor and Dean of the National School of Tropical Medicine at Baylor and Co-Director of the Texas Children's Hospital Center for Vaccine Development. "Widespread and global vaccination with our Texas Children's-Baylor-BE vaccine would also forestall the emergence of new variants. We have previously missed that opportunity for the alpha and delta variant. Now is our chance to prevent a new global wave from what might follow."

"Over the years, we have worked to make quality vaccines and pharmaceutical products accessible to families around the world. With this as our backdrop, we resolved to develop an affordable and effective COVID-19 vaccine. It has now become a reality. We deeply appreciate Texas Children's Hospital Center for Vaccine Development, Baylor, CEPI, the Bill and Melinda Gates Foundation, and the government of India for their continuous support and cooperation during this journey. The combined efforts & unceasing support demonstrate that we can collectively overcome any challenge".

Mahima Datla, Managing Director, Biological E. Limited

ABOUT TEXAS CHILDREN'S HOSPITAL
Texas Children's Hospital, a not-for-profit health care organization, is committed to creating a healthier future for children and women throughout the global community by leading in patient care, education and research. Consistently ranked as the best children's hospital in Texas, and among the top in the nation, Texas Children's has garnered widespread recognition for its expertise and breakthroughs in pediatric and women's health. The hospital includes the Jan and Dan Duncan Neurological Research Institute; the Feigin Tower for pediatric research; Texas Children's Pavilion for Women, a comprehensive obstetrics/gynecology facility focusing on high-risk births; Texas Children's Hospital West Campus, a community hospital in suburban West Houston; and Texas Children's Hospital The Woodlands, the first hospital devoted to children's care for communities north of Houston. The organization also created Texas Children's HealthPlan, the nation's first HMO for children; has the largest pediatric primary care network in the country, Texas Children's Pediatrics; Texas Children's Urgent Care clinics that specialize in after-hours care tailored specifically for children; and a global health program that's channeling care to children and women all over the world. Texas Children's Global Health program leads efforts that advance health care equity through innovative collaboration in care, education and research for underserved populations globally. Texas Children's Hospital is affiliated with Baylor College of Medicine. 

ABOUT TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT
Texas Children's Hospital Center for Vaccine Development is one of the leading vaccine development centers in the world. Established in Washington DC as the Sabin Vaccine Institute Product Development Partnership (PDP) in the year 2000 and after relocating to the Texas Medical Center in 2011, it rebranded as Texas Children's Center for Vaccine Development. For the past two decades it has acquired an international reputation as a non-profit PDP, advancing vaccines for poverty-related neglected tropical diseases (NTDs) and emerging infectious diseases of pandemic importance. In addition, it builds and strengthens capacity for vaccine development locally and with foreign nations and leads global efforts to guide and influence vaccine policy and advocacy through "vaccine diplomacy" as an international bridge for peace and vaccine development capacity.

ABOUT BCM VENTURES
Baylor College of Medicine Ventures is the commercial engine of the health sciences university, created to support the translation of academic knowledge and intellectual assets for the benefit of society. We do this by engaging university innovators, entrepreneurs and industry to fully develop ideas along their best commercial path. We foster a culture of commercialization and engage with industry to identify market opportunities for collaborative ventures. 

ABOUT BIOLOGICAL E. LIMITED
Biological E. Limited (BE), a Hyderabad-based Pharmaceuticals & Biologics Company founded in 1953, is the first private sector biological products company in India and the first pharmaceutical company in Southern India. BE develops, manufactures and supplies vaccines and therapeutics. BE supplies its vaccines to over 100 countries and its therapeutic products are sold in India and the USA. BE currently has 8 WHO-prequalified vaccines in its portfolio. In recent years, BE has embarked on new initiatives for organisational expansion such as developing generic injectable products for the regulated markets, exploring synthetic biology and metabolic engineering as a means to manufacture APIs sustainably and developing novel vaccines for the global market. 

Spotlight

Artificial Intelligence (AI) is everywhere, The purpose of this AI channel by Ramakrishnan Viswanathan is to showcase some of the great AI Initiatives across industries, AI trends from leading analyst, AI news across the globe, AI technologies, AI innovations and many more on AI

Spotlight

Artificial Intelligence (AI) is everywhere, The purpose of this AI channel by Ramakrishnan Viswanathan is to showcase some of the great AI Initiatives across industries, AI trends from leading analyst, AI news across the globe, AI technologies, AI innovations and many more on AI

Related News

FUTURE OF HEALTHCARE, HEALTHCARE ANALYTICS

Stericycle Completes Divestiture of Communication Solutions Business to Carenet Health

Stericycle, Inc. | December 05, 2022

Stericycle, Inc. a leading provider of regulated medical waste management and secure information destruction solutions, announced that it has completed the divestiture of its Communication Solutions business to Carenet Health, one of the healthcare industry’s leading consumer engagement and telehealth partners, for approximately $45 million in cash, subject to customary adjustments. Stericycle intends to use the net proceeds from the divestiture to pay down outstanding debt. Stericycle Communication Solutions provides online scheduling, automated messaging and strategic inbound and outbound call center services to drive patient access, action and adherence. For the nine months ended September 30, 2022, the Communication Solutions business had revenues of approximately $45 million, reported in the North America segment, as part of Regulated Waste and Compliance Services revenues. In connection with the closing, Stericycle and Carenet Health entered into a purchase and transition services agreements. The divested business includes approximately 500 team members in North America. “The sale of Stericycle Communication Solutions demonstrates our continued commitment to deliver on our portfolio optimization key business priority, marking our eleventh divestiture since 2019. By further streamlining our company, we are taking another step in our journey to focus on our core businesses and improve sustainable operational efficiencies. I would like to thank our team members transitioning to Carenet Health and wish them much success as they work to deliver better experiences and outcomes across the patient journey." Cindy J. Miller, chief executive officer of Stericycle About Carenet Health Carenet Health is one of the healthcare industry’s leading consumer engagement and telehealth partners—providing consumer engagement, clinical support, virtual care and advocacy solutions on behalf of 250+ of the nation’s premier health plans, providers, health systems and Fortune 500 companies. One in four Americans have access to Carenet’s services. Carenet is headquartered in San Antonio, Texas, with additional office locations in New Mexico, Maine and the Philippines. About Stericycle Stericycle, Inc., is a U.S. based business-to-business services company and leading provider of compliance-based solutions that protects people and brands, promotes health and well-being, and safeguards the environment. Stericycle serves customers in the U.S. and 16 countries with solutions for regulated waste and compliance services and secure information destruction.

Read More

HEALTHTECH SECURITY, DIGITAL HEALTHCARE

CHA Hollywood Presbyterian Medical Center Launches Fetal Surgery Program

CHA Hollywood Presbyterian Medical Center | January 23, 2023

Hollywood Presbyterian Medical Center (CHA HPMC), a member of CHA Health Systems, recently announced a new partnership with Los Angeles Fetal Surgery to provide life-saving and revolutionary fetal surgery to pregnant women and their unborn babies with birth defects. It will be the only fetal surgery center in the U.S. Los Angeles Fetal Surgery, a joint program between USC and Children's Hospital Los Angeles, offers minimally invasive fetal treatments to reduce or cure adverse outcomes due to fatal conditions, which would otherwise result in the baby's death or irreversible organ damage. Dr. Ramen Chmait, an international expert in minimally invasive fetal surgery, will direct the program. He has produced over 200 manuscripts and book chapters in fetal medicine and surgery over the past 20 years. "The goal of the Los Angeles Fetal Surgery Program at CHA Hollywood Presbyterian is to treat unborn babies with innovative treatments while providing families with emotional support," said Ramen Chmait, MD, who also serves as an OB-GYN with Keck Medicine of USC. (Source- Business Wire) "Our collaborative structure ensures our patients have access to a wide variety of services and specialists. This affiliation with CHA HPMC only strengthens our commitment to successful outcomes,” he further added. (Source- Business Wire) According to the CDC, 1 in 33 U.S. newborns is born with a serious condition. The program will treat Spina Bifida, Vasa Previa, and Twin-Twin Transfusion Syndrome. CHA HPMC, Los Angeles' second-largest maternity center, provides excellent prenatal and postpartum care. Fetal surgery will help CHA HPMC serve its community and improve results for expectant families. About CHA Hollywood Presbyterian Medical Center CHA Hollywood Presbyterian Medical Center (CHA HPMC) is a full-service hospital, providing acute care to the multicultural population of Hollywood and its neighboring regions since 1924. CHA Bio Group is known worldwide for its high-quality health care and advances in reproductive medicine. CHA HPMC has 469 acute care beds and 89 skilled nursing beds. The hospital employs about 550 doctors from 69 disciplines and 75 nationalities. It treats its various multicultural patients with kindness and compassion. CHA Health Systems, a dynamic global healthcare corporation with 86 hospitals and clinics, 30 research and 14 education institutes, along with 31 bio/pharmaceutical/healthcare enterprises, provides a wide range of services in seven countries.

Read More

DIGITAL HEALTHCARE

CipherHealth and SADA Collaborate to Improve Patient Care Via Looker

CipherHealth | January 06, 2023

CipherHealth, a leader in patient engagement technology and communication solutions, recently teamed up with SADA, an award-winning Google Cloud Partner, to use Google Cloud's Looker to collect socioeconomic data to improve patient care. With this new feature, CipherHealth aims to empower healthcare leaders by enabling them to collect large volumes of data and assist patients and medical professionals at each point of the care journey. Earlier, CipherHealth's platform gave doctors and nurses complete conversational and clinical information about each patient. It worked with SADA, a company that knows how to set up and run Google Cloud's analytics platform Looker, to add self-service analytics to the platform and make it more useful. With the help of Looker Embedded Analytics, CipherHealth has made it easier for its clients to access this data for analysis and visualization at any time during the patient's life. As a result of the partnership, CipherHealth's clients, which include 500 hospitals across the country, will now have access to patient data about social determinants of health (SDOH). Also, they can use in-built analytics to divide patient groups and send personalized messages to each of them separately. With this information, CipherHealth's clients can zero in on a specific patient and find out what kind of treatment they need, along with any special accommodations (like if they have trouble making appointments). CipherHealth is HIPAA-compliant, meaning it may safely analyze and transfer clients' protected health information (PHI) over the internet. The company believes combining SADA with Google Cloud can give its clients a new view of their patient populations. It will also allow the company to make changes to its care delivery that are good for patients. In line with this, SADA said that the integration of Looker from Google Cloud improves the patient experience for CipherHealth and its clients. About CipherHealth CipherHealth is a proven technology solutions partner dedicated to improving patient communication and care. Since 2009, the company has helped build the market for patient engagement by making innovative tools that help providers give excellent care. The range of patient engagement programs from CipherHealth sets new standards for care and provides healthcare businesses with the tools they need to have meaningful conversations with their patients.

Read More